Jump to Main Content
Impact of MCP-1 and CCR-2 gene polymorphisms on coronary artery disease susceptibility
- Lin, Hsiu-Ling, Ueng, Kwo-Chang, Hsieh, Yih-Shou, Chiang, Whei-Ling, Yang, Shun-Fa, Chu, Shu-Chen
- Molecular biology reports 2012 v.39 no.9 pp. 9023-9030
- CCR2 receptor, alleles, chemokine CCL2, coronary artery disease, death, disease resistance, endothelial cells, genotype, macrophages, monocytes, myocytes, patients, polymerase chain reaction, restriction fragment length polymorphism, risk, smooth muscle, Taiwan
- Coronary artery disease (CAD) was the second leading cause of death during the last 3 years in Taiwan. Smooth muscle cells, monocytes/macrophages, and endothelial cells produce monocyte chemoattractant protein-1 (MCP-1) within atherosclerotic plaques following binding to the chemokine receptor-2 (CCR-2). Previous studies have well-documented the association between MCP-1 expression and susceptibility to, or clinicopathological features, of CAD. This study investigated the relationships between MCP-1-2518A/G and CCR-2-V64I genetic polymorphisms and CAD in the Taiwanese population. A total of 608 subjects, including 392 non-CAD controls and 216 patients with CAD, were recruited and subjected to polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) to evaluate the effects of these two polymorphic variants on CAD. Results indicated a significant association between MCP-1 -2548 gene polymorphism and susceptibility to CAD. GG genotypes (OR = 1.629; 95 % CI = 1.003–2.644), or individuals with at least one G allele (OR = 1.511; 95 % CI = 1.006–2.270), had a higher risk of CAD as compared with AA genotypes. Results also revealed that subjects with at least one A allele of the V64I CCR2 gene polymorphism had significantly increased risk of CAD. G allele in MCP-1-2518 might contribute to higher prevalence of atrial fibrillation in CAD patients (OR = 4.254; p < 0.05). In conclusion, MCP-1-2518G and CCR-2 64I gene polymorphisms represent important factors in determining susceptibility to CAD, and the contribution of MCP-1-2518G could be through effects on atrial fibrillation in CAD patients.